Nkarta, Inc. (NKTX)

US — Healthcare Sector
Peers: GLUE  LYEL  GBIO  SANA    PASG  BDTX  TCRR  HARP  ALEC  IPSC  KZR  MLYS  NGM  RVMD  BCEL 

Automate Your Wheel Strategy on NKTX

With Tiblio's Option Bot, you can configure your own wheel strategy including NKTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NKTX
  • Rev/Share 0.0
  • Book/Share 5.1248
  • PB 0.3395
  • Debt/Equity 0.2083
  • CurrentRatio 14.4781
  • ROIC -0.2826

 

  • MktCap 123466224.0
  • FreeCF/Share -1.428
  • PFCF -1.1697
  • PE -1.156
  • Debt/Assets 0.1677
  • DivYield 0
  • ROE -0.2663

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade NKTX William Blair Outperform Market Perform -- -- May 15, 2025
Initiation NKTX Rodman & Renshaw -- Buy -- $14 Oct. 9, 2024

News

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
NKTX
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
Nkarta (NKTX) Upgraded to Buy: Here's Why
NKTX
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Nkarta (NKTX) Upgraded to Buy: Here's Why
Nkarta: Grinding Lower, Trying To Find Support
NKTX
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Positive

Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with sufficient cash reserves to support ongoing research and development activities. Strengths include cutting-edge technology and strategic partnerships, while risks involve clinical trial uncertainties and regulatory hurdles.

Read More
image for news Nkarta: Grinding Lower, Trying To Find Support
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NKTX
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Negative

The heavy selling pressure might have exhausted for Nkarta (NKTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Read More
image for news Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nkarta to Participate in March Investor Conferences
NKTX
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences:

Read More
image for news Nkarta to Participate in March Investor Conferences

About Nkarta, Inc. (NKTX)

  • IPO Date 2020-07-10
  • Website https://www.nkartatx.com
  • Industry Biotechnology
  • CEO Mr. Paul J. Hastings
  • Employees 157

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.